Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram

Clinical and Experimental Immunology

Volumn 108, Issue 3, 1997, Pages 415-419

  Nyman, U ^a   Mussener A ^a   Larsson, E ^a   Lorentzen, J ^a   Klareskog, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

arthritis; collagen II; Rolipram

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; ROLIPRAM;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030904664     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.3931291.x     Document Type: Article

References (17)

1. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146:857-68.
2. Courtenay JS, Dallman MJ, Dayan AD et al. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980; 283:666-8.
3. Holmdahl R, Jansson L, Gullberg D et al. Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of heterologous and autologous collagen II. Clin Exp Immunol 1985; 62:639-46.
4. Müssener Å, Klareskog L, Lorentzen J, Kleinau S. TNF-alpha dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen- and oil-induced arthritis. Scand J Immunol 1995; 42:128-34.
5. Elliot MJ, Maini RM, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.
6. Taffet SM, Singhel KJ, Overholtzer JF, Shurtleff SA. Regulation of tumor necrosis factor expression in a macrophage like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol 1989; 120:291-300.
7. Endres S, Fülle HJ, Sinha B et al. Cyclic nucleotides differentially regulate the synthesis of tumor necrosis factor alpha and interleukin 1β by human mononuclear cells. Immunology 1991; 72:56-60.
8. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor Rolipram suppresses tumor necrosis factor alpha production by human mononuclear cells. Int J Immunopharmacol 1993; 15:3:409-13.
9. Tannenbaum CS, Hamilton TA. Lipopolysaccharide-induced gene exprerssion in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 1989; 142:1274-80.
10. Sommer N, Löschmann PA, Northoff GH et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1995; 1:244-8.
11. Smith BD, Martin GR, Miller EJ, Dorfman A, Swarm R. Nature of the collagen synthesized by a transplanted chondrosarcoma. Arch Biochem Biophys 1975; 166:181-6.
12. Andersson ME, Holmdahl R. Analysis of type II collagen reactive T cells in the mouse. Different regulation of autoreactive vs. non-autoreactive anti-type II collagen T cells in the DBA/1 mouse. Eur J Immunol 1990; 20:1061-6.
13. Lorentzen JC, Erlandsson H, Müssener Å et al. Specific and long-lasting protection from collagen-induced arthritis and oil-induced arthritis in DA rats by administration of immunogens. Scand J Immunol 1995; 42:82-89.
14. Artursson K, Gobl A, Lindersson M, Johansson M, Alm G. Molecular cloning of gene encoding porcrine IFN-β. J Interferon Res 1992; 12:153-60.
15. Williams RO, Feldman M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-8.
16. Genain CP. Prevention of autoimmune demyelination in non-human primates by a c-AMP-specific phosphodiesterase inhibitor. PNAS USA 1995; 92:3601-5.
17. Sekut L, Yarnell D, Stimpson SA et al. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 1995; 100:126-32.